Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined rhEPO and iron sucrose to reduce transfusion in CABG surgery
ChiCTR2200066165Phase 4Not yet recruiting
- Sponsor
- Fuwai Hospital
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis and anaemia comparing Control group (iron sucrose alone) with Test group (iron sucrose + rhEPO) (2 arms). Primary endpoint: Perioperative transfusion rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
iron sucroseepoetin alfa
03
Conditions
coronary arteriosclerosisanaemia
Beyond the preview
Go deeper on ChiCTR2200066165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066165.